KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Non-Current Debt (2022 - 2025)

Biogen has reported Non-Current Debt over the past 9 years, most recently at $6.3 billion for Q4 2025.

  • Quarterly results put Non-Current Debt at $6.3 billion for Q4 2025, up 38.26% from a year ago — trailing twelve months through Dec 2025 was $6.3 billion (up 38.26% YoY), and the annual figure for FY2025 was $6.3 billion, up 38.26%.
  • Non-Current Debt for Q4 2025 was $6.3 billion at Biogen, up from $4.5 billion in the prior quarter.
  • Over the last five years, Non-Current Debt for BIIB hit a ceiling of $6.8 billion in Q4 2023 and a floor of $4.5 billion in Q4 2024.
  • Median Non-Current Debt over the past 4 years was $6.3 billion (2022), compared with a mean of $6.0 billion.
  • Biggest five-year swings in Non-Current Debt: plummeted 33.01% in 2024 and later skyrocketed 38.26% in 2025.
  • Biogen's Non-Current Debt stood at $6.3 billion in 2022, then increased by 8.08% to $6.8 billion in 2023, then plummeted by 33.01% to $4.5 billion in 2024, then skyrocketed by 38.26% to $6.3 billion in 2025.
  • The last three reported values for Non-Current Debt were $6.3 billion (Q4 2025), $4.5 billion (Q4 2024), and $6.8 billion (Q4 2023) per Business Quant data.